Payer-addressable burden of crohn's disease in members treated with biologics in the United States : actuarial analysis findings from RAINBOW

<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<rdf:Description>
<dc:date>2023-12-04</dc:date>
<dc:description xml:lang="es">Sumario: Payer-addressable burden (PAB) reflects how real-orld disease-associated costs impact the per member per month (PMPM) budget of a health plan, and can help to delineate drivers of PMPM costs and inform cost-management strategies for diseases with a high cost burden, such as Crohn's disease (CD). We aimed to evaluate the U.S. PAB of CD anaged with biologics. Weighted mean costs per member with CD in the commercial health plan population between 2017 and 2019 were evaluated from a health plan actuarial perspective. In addition to the overall population of members with CD treated with adalimumab, infliximab, vedolizumab, or ustekinumab, the subpopulations of members who were naive to biologic therapies at treatment initiation and/or treatment-adherent members were also analyzed. The analyses we present here highlight that treatments and patient subgroups with lower PMPM costs are important focus areas for payers in terms of identifying strategies to manage the budget for CD in a U.S. plan population</dc:description>
<dc:identifier>https://documentacion.fundacionmapfre.org/documentacion/publico/es/bib/184642.do</dc:identifier>
<dc:language>spa</dc:language>
<dc:rights xml:lang="es">InC - http://rightsstatements.org/vocab/InC/1.0/</dc:rights>
<dc:subject xml:lang="es">Cálculo actuarial</dc:subject>
<dc:subject xml:lang="es">Contabilidad de costes</dc:subject>
<dc:subject xml:lang="es">Enfermedades</dc:subject>
<dc:subject xml:lang="es">Análisis demográfico</dc:subject>
<dc:subject xml:lang="es">Tratamiento médico</dc:subject>
<dc:type xml:lang="es">Artículos y capítulos</dc:type>
<dc:title xml:lang="es">Payer-addressable burden of crohn's disease in members treated with biologics in the United States : actuarial analysis findings from RAINBOW</dc:title>
<dc:relation xml:lang="es">En: North American actuarial journal. - Schaumburg : Society of Actuaries, 1997- = ISSN 1092-0277. - 04/12/2023 Tomo 27 Número 4 - 2023 , p. 619-629</dc:relation>
</rdf:Description>
</rdf:RDF>